Ranking the Top 10 Pharmaceutical Companies and Pharmaceutical Drugs by revenue, market share, and growth trends 2017-2025
The global pharmaceutical industry is expected to reach $1.3 trillion by 2025, growing at 5.0% per year (CAGR) between 2019 and 2025. Pfizer will be the leading prescription drug company in 2025, growing at 2.0% CAGR, with total sales of $52.3 billion, ahead of Novartis and Roche.
Top 10 Pharmaceutical Companies 2017-2025 ($billion)
Among the global top 10 pharmaceutical companies (Pfizer, Novartis, Roche, Johnson & Johnson, Merck & Co., Sanofi, GlaxoSmithKline, AbbVie, AstraZeneca, and Takeda), Pfizer will be the leading prescription drug competition in 2025 with sales of $52.3 billion, ahead of Novartis and Roche.
However, Takeda is anticipated to grow at a faster rate of 10.3% CAGR over the forecast period and might claim the number one position by 2025.
- Novartis acquired number two position after exhibiting 2.3% compound average growth rate (CAGR) between 2019-25, as opposed to Roche’s 0.8% CAGR.
- By 2025, Navartis is likely to ranked at number two with sales of $50.9 billion, and Roche at number three position with sales of $47.1 billion.
- Bristol-Myers Squibb has lost its position in the top 10 global pharmaceuticals, due to loss of Opdivo market share to Keytruda and the recent acquisition of Shire by Takeda. However, Bristol-Myers Squibb’s recent announcement of acquisition of Celgene might bring it back to the top 10 compoanies.
- Takeda has advanced its ranking to seventh place between 2019 and 2025 with an impressive 10.8% CAGR.
- AstraZeneca has also shown impressive 7.7% CAGR, due to breakthroughs in the Chinese market and high sales of its oncology products Tagrisso and Lynparza.
- Only Takeda and AstraZeneca would be able to increase market share between 2017 and 2025.
- Overall, the top 10 pharmaceutical companies showed -6.6% market share growth, with Roche alone contributing -1.4% CAGR to the total market.
Top 10 Pharmaceutical Drugs 2017-2025 ($billion)
Among the top 10 pharmaceutical drugs (Humira, Keytruda, Eliquis, Opdivo, 5Imbruvica, Ibrance, Revlimid, Stelara, Eylea and Biktarvy), AbbVie’s blockbuster Humira was a top selling drug worldwide in 2017 with sales of $18.9 billion.
However, Humira is expected lose its top position to Keytruda due to adalimumab biosimilar entry in the Europe and expected U.S. biosimilar competition over the forecast period. Humira’s market growth is anticipated at a -8.3% CAGR during 2019-2025.
- Keytruda in terms of product sales, positive data from ongoing clinical trials and further FDA approvals, expected to overtake Humira to be the number one position with forecasted sales of US$19.6 billion by 2025, growing at a CAGR of 14.2% over the forecast period.
- The worldwide sales of Revlimid are expected to decline with a CAGR of -3.3% between 2019 and 2025 to $7.7 billion, due to generic versions expected to hit the U.S. market in 2022.
- Bristol-Myers Squibb’s Eliquis is expected to grow at a 10.4% CAGR reaching $13.3 billion during the next 5 years.
- The checkpoint inhibitor Opdivo continues to have strong sales of $12.1 billion, with a 6.7% CAGR in the anti-neoplastic MAbs segment over the forecast period 2019-2025.
- Gilead’s Biktarvy continues to outshine all other HIV medications and climbs a place to sit in the top 10 this year, boasting an impressive CAGR of 27.8% going into 2025 and sales of $9.3 billion.
Source: EvaluatePharma, iHealthcareAnalyst, Inc.
